{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir&page=4",
    "query": {
      "intervention": "Cabotegravir",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 83,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:04:43.003Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04973254",
      "title": "Improving Treatment and Retention Adherence in Nontraditional Settings",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CAB-RPV LA",
          "type": "OTHER"
        },
        {
          "name": "Standard treatment within an HIV clinic",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2022-02-23",
      "completion_date": "2023-03-28",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04973254"
    },
    {
      "nct_id": "NCT06451341",
      "title": "IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Acceptability of Intervention Measure (AIM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Intervention Appropriateness Measure (IAM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Feasibility of Intervention Measure (FIM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "HIV Stigma Scale Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Needs and Barriers Assessment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pre-visit Outreach",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Qualitative interview - patient participants",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Staff education",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Staff Month 7 and 15 Survey - Staff Burden and Engagement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Qualitative interview - staff",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2024-07-01",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 4,
      "location_summary": "Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more",
      "locations": [
        {
          "city": "Harlan",
          "state": "Iowa"
        },
        {
          "city": "Shenandoah",
          "state": "Iowa"
        },
        {
          "city": "Grand Island",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451341"
    },
    {
      "nct_id": "NCT07939529",
      "title": "People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Viremia"
      ],
      "interventions": [
        {
          "name": "Lenacapavir",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir",
          "type": "DRUG"
        },
        {
          "name": "Bictegravir/Emtricitabine/Tenofovir Alafenamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2028-02-01",
      "completion_date": "2030-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07939529"
    },
    {
      "nct_id": "NCT03635788",
      "title": "The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Standard of Care (SOC) Oral ART",
          "type": "DRUG"
        },
        {
          "name": "Oral RPV",
          "type": "DRUG"
        },
        {
          "name": "Oral CAB",
          "type": "DRUG"
        },
        {
          "name": "RPV-LA Loading Dose",
          "type": "DRUG"
        },
        {
          "name": "CAB-LA Loading Dose",
          "type": "DRUG"
        },
        {
          "name": "RPV-LA Maintenance Dose",
          "type": "DRUG"
        },
        {
          "name": "CAB-LA Maintenance Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 456,
      "start_date": "2019-03-28",
      "completion_date": "2026-08-17",
      "has_results": true,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635788"
    },
    {
      "nct_id": "NCT01648257",
      "title": "Relative Bioavailability Study of GSK1265744 Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Human Immunodeficiency Virus and Hepatitis"
      ],
      "interventions": [
        {
          "name": "GSK1265744 Na Salt Tablets",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 Free Acid Nanomilled Capsules",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 Free Acid Micronized Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 18,
      "start_date": "2012-08",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2016-08-12",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01648257"
    },
    {
      "nct_id": "NCT01467531",
      "title": "A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Human Immunodeficiency Virus and Hepatitis"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Rlipivirine",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-11",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2012-10-15",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01467531"
    },
    {
      "nct_id": "NCT06145854",
      "title": "Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hiv"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Injection [Apretude]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Midway Specialty Care Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2024-01-02",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Temple Terrace, Florida • West Palm Beach, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Temple Terrace",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06145854"
    },
    {
      "nct_id": "NCT04484337",
      "title": "Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir sodium (Oral Lead In)",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 400 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 200 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Topical Non-steroidal anti-inflammatory drug (NSAID)",
          "type": "DRUG"
        },
        {
          "name": "Topical steroid",
          "type": "DRUG"
        },
        {
          "name": "Topical NSAID placebo",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        },
        {
          "name": "Topical steroid placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 138,
      "start_date": "2020-07-31",
      "completion_date": "2023-05-05",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484337"
    },
    {
      "nct_id": "NCT02951052",
      "title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir (CAB) tablet",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine (RPV) tablet",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir - Injectable Suspension (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine - Injectable Suspension (RPV LA)",
          "type": "DRUG"
        },
        {
          "name": "2 NRTIs plus an INI, NNRTI, or PI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 618,
      "start_date": "2016-10-28",
      "completion_date": "2029-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02951052"
    },
    {
      "nct_id": "NCT06033547",
      "title": "A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Formulation F",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir Formulation G",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2023-09-12",
      "completion_date": "2025-07-25",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-11-19T02:04:43.003Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06033547"
    }
  ]
}